CDK4-6 Inhibitors: Evaluation of Efficacy in Cases of Hormone Receptor-Positive HER2-Negative Breast Cancer with Only Bone Metastasis

Objective: Bone is the most common site of metastasis in patients with hormone receptor (HR)-positive breast cancer. However, 17-37% of these patients with metastatic disease develop metastasis only in the bone. In this context, the present study aimed to compare the CDK4-6 inhibitors palbociclib an...

Full description

Bibliographic Details

Published in:	Journal of Oncological Sciences
Main Authors:	Serhat SEKMEK, Mirmehdi MEHTİYEV, Doğan BAYRAM, Gökhan UÇAR, Öznur BAL, Efnan ALGIN, Fahriye Tuğba KÖŞ, Burak CİVELEK, Doğan UNCU
Format:	Article
Language:	English
Published:	Turkish Society of Oncology 2025-04-01
Subjects:	breast cancer hormone-positive cancer bone metastasis cdk4-6 inhibitors
Online Access:	https://www.journalofoncology.org/articles/cdk4-6-inhibitors-evaluation-of-efficacy-in-cases-of-hormone-receptor-positive-her2-negative-breast-cancer-with-only-bone-metastasis/doi/jos.galenos.2024.2024.103871